Matching-Adjusted Indirect Comparison of Sotorasib Plus Panitumumab Versus Trifluridine/Tipiracil Plus Bevacizumab in Chemorefractory Metastatic Colorectal Cancer
Matching-Adjusted Indirect Comparison of Sotorasib Plus Panitumumab Versus Trifluridine/Tipiracil Plus Bevacizumab in Chemorefractory Metastatic Colorectal Cancer. // Clinical Colorectal Cancer. – URL: https://www.sciencedirect.com/science/article/pii/S1533002826000265?dgcid=rss_sd_all
Matching-Adjusted Indirect Comparison of Sotorasib Plus Panitumumab Versus Trifluridine/Tipiracil Plus Bevacizumab in Chemorefractory Metastatic Colorectal Cancer. Clinical Colorectal Cancer. https://www.sciencedirect.com/science/article/pii/S1533002826000265?dgcid=rss_sd_all
“Matching-Adjusted Indirect Comparison of Sotorasib Plus Panitumumab Versus Trifluridine/Tipiracil Plus Bevacizumab in Chemorefractory Metastatic Colorectal Cancer.” Clinical Colorectal Cancer.
@article{article40596,
title = {Matching-Adjusted Indirect Comparison of Sotorasib Plus Panitumumab Versus Trifluridine/Tipiracil Plus Bevacizumab in Chemorefractory Metastatic Colorectal Cancer},
journal = {Clinical Colorectal Cancer},
url = {https://www.sciencedirect.com/science/article/pii/S1533002826000265?dgcid=rss_sd_all}
}